Michael is a consultant neurologist in the department of neurology at the University of Ulm in Germany, and scientific projects manager for the European Huntington’s disease network. Michael trained ...

Please consider making a donation if you value the services that HDBuzz provides. We want HDBuzz to be sustainable so that we can continue to report unbiased science to the HD community. With your ...

Siddharth is an MD/PhD candidate in Dr. Ray Truant’s lab at McMaster University in Hamilton, Canada. Prior to this, he obtained an Honours Bachelor of Science in Biochemistry, also from McMaster. His ...

Emmy-award winning tv journalist, Charles Sabine, has worked for the us network NBC news for 26 years. That career took him, via twelve wars, six revolutions, and four earthquakes, to most of the news ...

HDBuzz content is written by scientists for the global HD community. It is free to use and share. We want our content to reach as many people as possible. HDBuzz is licensed under a Creative Commons ...

In plain language. Written by scientists. For the global HD community.

Please consider making a donation if you value the services that HDBuzz provides. We want HDBuzz to be sustainable so that we can continue to report unbiased science to the HD community. With your ...

Please consider making a donation if you value the services that HDBuzz provides. We want HDBuzz to be sustainable so that we can continue to report unbiased science to the HD community. With your ...

In an update shared today, uniQure announced alignment with the US drug regulator on key criteria for accelerated approval of ...

On December 3, 2024 we received word that the very first person received a new drug, called ALN-HTT02, as part of a Phase 1 trial aiming to treat Huntington’s disease (HD). Going boldly as the first ...